|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a non-consanguineous pedigree composed by several individuals with short stature, including 2 pediatric patients with typical diagnosis of isolated growth hormone deficiency (IGHD) and 4 other siblings with severe short stature, low serum IGF-1 and IGFBP-3, but normal stimulated GH levels, suggesting growth hormone insensitivity (GHI) in the latter group.
|
31835104 |
2020 |
|
Isolated somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nonspecific skeletal abnormalities were frequently noticed, and normal to elevated plasma IGF-I levels were observed in all except 1 patient with growth hormone deficiency.
|
31715605 |
2019 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
When implanted in rats with growth hormone deficiency and irradiated with an NIR light from the outside skin, the device exhibits profiles of hGH and IGF1 plasma concentrations, as well as body weight change, similar to those in animals treated with conventional s.c. hGH injections.
|
31123147 |
2019 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth hormone (GH) stimulation tests were performed 3-4 years post TBI in children with GH deficiency (GHD) 1 year post TBI and in all children with low height velocity (<-1 DS) or low IGF-1 (<-2 DS).
|
30884465 |
2019 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-1 assessed by pubertal status has the best positive predictive power for GH deficiency diagnosis in peripubertal children.
|
30676998 |
2019 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of the Choice of IGF-I Assay and Normative Dataset on the Diagnosis and Treatment of Growth Hormone Deficiency in Children.
|
30286459 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the reciprocal associations between bone formation markers [alkaline phosphatase (ALP), bone alkaline phosphatase (BALP)], the GH/IGF-1 axis and 25-hydroxyvitamin D [25(OH)D] in children with growth hormone deficiency at baseline and during recombinant human growth hormone (rhGH) therapy.
|
29649340 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low IGF-1 levels despite normal weight/adequate nutrition were observed in six patients, suggesting growth hormone deficiency similar to PWS.
|
29496979 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
AGHDA = Assessment of Growth Hormone Deficiency in Adulthood; CHOox = carbohydrate oxidation; ET = ejection time; fT3 = free triiodothyronine; fT4 = free thyroxine; GH = growth hormone; GHD = growth hormone deficiency; HB-RQ = high baseline respiratory quotient; HPT = hypothalamic-pituitary-thyroid; ICT = isovolumetric contraction time; IGF-1 = insulin-like growth factor 1; IRT = isovolumetric relaxation time; LB-RQ = low baseline respiratory quotient; LV = left ventricular; NHP = Nottingham Health Profile; QOL = quality of life; REE = resting energy expenditure; RQ = respiratory quotient; rT3 = reverse triiodothyronine; SF-36 = Short Form 36; TSH = thyroid-stimulating hormone; T3 = triiodothyronine; T4 = thyroxine; TT3 = total triiodothyronine; TT4 = total thyroxine.
|
29658834 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No significant association of indices of growth hormone deficiency (IGF-1-level-SDS, years of unsubstituted growth hormone deficiency etc.) with telomere length was detected.
|
30352410 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline Insulin like growth factor binding protein 3 (IGFBP - 3) along with ∆ IGF - 1 in the first 3 months of GH therapy level can be a marker of growth response to the rGH and/or rIGF - 1 therapy in children with non - growth hormone deficiency short stature.
|
30197657 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Determination of serum levels of GH and IGF-I is crucial for the diagnosis and treatment of GH deficiency and disorders related to GH excess such as acromegaly and pituitary gigantism.
|
30378780 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Utility of serum IGF-1 for diagnosis of growth hormone deficiency following traumatic brain injury and sport-related concussion.
|
29609574 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Predictive Value of Insulin-Like Growth Factor 1 in Irradiation-Dependent Growth Hormone Deficiency in Childhood Cancer Survivors.
|
30645996 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Disagreement in normative IGF-I levels may lead to different clinical interpretations and GH dose adjustments in GH deficiency.
|
28977695 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-1 results may differ after switching from an older immunoassay to a consensus-compliant assay such as LC-MS. Clinicians should consider the potential impact of assay switching before altering treatment due to discrepant results, particularly in patients monitored over time, such as those with acromegaly and GH deficiency.
|
29218459 |
2018 |
|
Isolated somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate serum IGF-I SDS levels during GH treatment in children with GH deficiency, and to identify potential determinants of these levels.
|
28760908 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Measurement of the levels of growth hormone (GH) and its related factor insulin-like growth factor I (IGF-I) is essential for the diagnosis and treatment of GH deficiency (GHD) and conditions related to excess GH such as acromegaly and pituitary gigantism.
|
28516748 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Serum insulin-like growth factor-1 and peak growth hormone (GH) levels following GH stimulation tests were significantly lower in patients with CPHD than in those with IGHD (p<0.05).
|
28332357 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate gender differences in GH dosing, IGF-I and cardiovascular risk markers in adults with GH deficiency (GHD).
|
28306165 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationship between IGF-I Concentration and Metabolic Profile in Children with Growth Hormone Deficiency: The Influence of Children's Nutritional State as well as the Ghrelin, Leptin, Adiponectin, and Resistin Serum Concentrations.
|
28596789 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.
|
27520559 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
To describe the range of insulin-like growth factor-I (IGF-I) z-score values (IGF-Iz) and growth hormone (GH) dose adjustments in pre-pubertal patients with GH deficiency (GHD) treated with GH in a single tertiary care center.
|
28150584 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
We measured blood pressure, lipids, hemoglobin HbA1c, IGF-1, IGFBP-3, and cIMT in 28 children treated with supraphysiological doses of GH (mean age 9.8 ± 2.2 years, 39% males) and 36 children suffering from GH deficiency (GHD) and treated with physiological doses of GH (mean age 9.7 ± 2.2 years, 72% males) in a longitudinal study over 3 years.
|
28068655 |
2017 |
|
Isolated somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Their sister presented at 16 years with classic GH deficiency (peak GH <0.1 μg/liter, IGF-1 <3.3 mmol/liter) and attained an untreated near-adult height of 144 cm (-3.0 SDS); the tallest untreated patient with GHRHR mutations reported.
|
27501283 |
2016 |